Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2025 Status changed from recruiting to active, no longer recruiting.
19 May 2025 According a Reunion Neuroscience media release, company announced the completion of patient enrollment and the last patient dosed in this trial and topline results from the study, which enrolled 84 patients, are anticipated in the third quarter of 2025.
07 Apr 2025 According a Reunion Neuroscience media release, company anticipates to present Initial data from RECONNECT are expected in mid-2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com